Calcipotriol/Betamethasone Dipropionate Cutaneous Foam Treatment for Psoriasis in Patients With BSA 5–15% and PGA ≥ 3: Post-Hoc Analysis From Three Randomized Controlled Trials

Calcipotriol/Betamethasone Dipropionate Cutaneous Foam Treatment for Psoriasis in Patients With BSA 5–15% and PGA ≥ 3: Post-Hoc Analysis From Three Randomized Controlled Trials

Abstract Introduction Psoriasis is a chronic, inflammatory disease, which ranges in severity from mild to severe. Although topical therapies are frequently used to treat mild disease, they are not routinely used to treat patients with moderate-to-severe disease who have a larger proportion of their...

Full description

Bibliographic Details
Main Authors: Lars Iversen, Merle Kurvits, Anja Marieke Snel-Prentø, Alan Menter
Format: Article
Language:English
Published: Adis, Springer Healthcare 2020-08-01
Series:Dermatology and Therapy
Subjects:
Betamethasone dipropionate
BSA ≥ 5%
Calcipotriol
Enstilar
Foam
Moderate-to-severe
Online Access:https://doi.org/10.1007/s13555-020-00419-2

Internet

https://doi.org/10.1007/s13555-020-00419-2

Similar Items